Access the full text.
Sign up today, get DeepDyve free for 14 days.
R. Jagsi, N. Sheets, Aleksandra Janković, Amy Motomura, S. Amarnath, P. Ubel (2009)
Frequency, nature, effects, and correlates of conflicts of interest in published clinical cancer researchCancer, 115
J. Peppercorn, E. Blood, E. Winer, Ann Partridge (2007)
Association between pharmaceutical involvement and outcomes in breast cancer clinical trialsCancer, 109
Dani Bidros, M. Vogelbaum (2009)
Novel drug delivery strategies in neuro-oncologyNeurotherapeutics, 6
Gisela Schott, Henry Pachl, Ulrich Limbach, U. Gundert-Remy, K. Lieb, W. Ludwig (2010)
The financing of drug trials by pharmaceutical companies and its consequences: part 2: a qualitative, systematic review of the literature on possible influences on authorship, access to trial data, and trial registration and publication.Deutsches Arzteblatt international, 107 17
Matthew McCoy, E. Emanuel (2017)
Why There Are No “Potential” Conflicts of InterestJAMA, 317
Gordon Sun, Jeffrey Steinberg, R. Jagsi (2012)
The calculus of national medical research policy--the United States versus Asia.The New England journal of medicine, 367 8
S. Lloyd, D. Buscariollo, C. Gross, D. Makarov, James Yu, S. Aneja (2012)
The Funding of Phase III Clinical Trials Examining Radiation Compared With That of Other ModalitiesInternational Journal of Radiation Oncology Biology Physics, 84
John Yaphe, R. Edman, Barry Knishkowy, Joseph Herman (2001)
The association between funding by commercial interests and study outcome in randomized controlled drug trials.Family practice, 18 6
F. Moraes, E. Leite, D. Hamstra, F. Feng, F. Arruda, R. Gadia, Carlos Abreu, G. Marta, S. Hanna, J. Silva, H. Carvalho, D. Spratt (2015)
Self-reported Conflicts of Interest and Trial Sponsorship of Clinical Trials in Prostate Cancer Involving RadiotherapyAmerican Journal of Clinical Oncology, 41
R. Riechelmann, Lisa Wang, A. O'Carroll, M. Krzyzanowska (2007)
Disclosure of conflicts of interest by authors of clinical trials and editorials in oncology.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 29
G Schott, H Pachl, U Limbach, U Gundert-Remy, WD Ludwig, K Lieb (2010)
The financing of drug trials by pharmaceutical companies and its consequences: part 1: a qualitative, systematic review of the literature on possible influences on the findings, protocols, and quality of drug trialsDtsch Aerzteblatt Int, 107
Gisela Schott, Henry Pachl, Ulrich Limbach, U. Gundert-Remy, W. Ludwig, K. Lieb (2010)
The financing of drug trials by pharmaceutical companies and its consequences. Part 1: a qualitative, systematic review of the literature on possible influences on the findings, protocols, and quality of drug trials.Deutsches Arzteblatt international, 107 16
G Schott, H Pachl, U Limbach, U Gundert-Remy, K Lieb, WD Ludwig (2010)
The financing of drug trials by pharmaceutical companies and its consequences: part 2: a qualitative, systematic review of the literature on possible influences on authorship, access to trial data, and trial registration and publicationDtsch Aerzteblatt Int, 107
B. Djulbegovic, M. Lacevic, A. Cantor, K. Fields, Charles Bennett, Jared Adams, N. Kuderer, G. Lyman (2000)
The uncertainty principle and industry-sponsored researchThe Lancet, 356
N. Cihoric, A. Tsikkinis, G. Minniti, F. Lagerwaard, U. Herrlinger, Etienne Mathier, I. Soldatovic, B. Jeremic, P. Ghadjar, O. Eliçin, K. Lössl, D. Aebersold, C. Belka, E. Herrmann, M. Niyazi (2017)
Current status and perspectives of interventional clinical trials for glioblastoma – analysis of ClinicalTrials.govRadiation Oncology (London, England), 12
C. Booth, D. Cescon, Lisa Wang, I. Tannock, M. Krzyzanowska (2008)
Evolution of the randomized controlled trial in oncology over three decades.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 33
H. Fineberg (2017)
Conflict of Interest: Why Does It Matter?JAMA, 317 17
P. Easterbrook, R. Gopalan, J. Berlin, D. Matthews (1991)
Publication bias in clinical researchThe Lancet, 337
L. Kjaergard, B. Als-Nielsen (2002)
Association between competing interests and authors' conclusions: epidemiological study of randomised clinical trials published in the BMJBMJ : British Medical Journal, 325
Hamilton III, E. Dorsey (2012)
Biomedical research in an age of austerity.JAMA, 308 22
B. Hirsch, R. Califf, S. Cheng, A. Tasneem, John Horton, K. Chiswell, K. Schulman, D. Dilts, A. Abernethy (2013)
Characteristics of oncology clinical trials: insights from a systematic analysis of ClinicalTrials.gov.JAMA internal medicine, 173 11
F. Moraes, Lorine Bonifácio, G. Marta, S. Hanna, Á. Atallah, V. Moraes, J. Silva, H. Carvalho (2015)
Hierarchy of evidence referring to the central nervous system in a high-impact radiation oncology journal: a 10-year assessment. Descriptive critical appraisal study.Sao Paulo medical journal = Revista paulista de medicina, 133 4
E. Dorsey, Jason Roulet, Joel Thompson, Jason Reminick, Ashley Thai, Zachary White-Stellato, C. Beck, B. George, H. Moses (2010)
Funding of US biomedical research, 2003-2008.JAMA, 303 2
S. Agrawal, N. Brennan, P. Budetti (2013)
The Sunshine Act--effects on physicians.The New England journal of medicine, 368 22
R. Davidson (1986)
Source of funding and outcome of clinical trialsJournal of General Internal Medicine, 1
F. Moraes, L. Mendez, N. Taunk, S. Raman, J. Suh, L. Souhami, B. Slotman, E. Weltman, D. Spratt, A. Berlin, G. Marta (2018)
Funding source, conflict of interest and positive conclusions in neuro-oncology clinical trialsJournal of Neuro-Oncology, 136
Propose To examine the association between trial sponsorship sources, self-reported conflicts of interest (COI), and study and author characteristics in central nervous system (CNS) oncology clinical trials (CT). Methods MEDLINE search was performed for original CT on “Central Nervous System Neoplasms“[Mesh]. The inves- tigators assessed for relationships between funding source (industry, academic or cooperative, none, not described), COI (presented, none, or not reported), CT, and author characteristics. Results From 2010 to 2015, 319 CT were considered eligible. The majority of the studies involved primary gliomas (55.2%) and were Phase II CT (59.2%). Drug therapy was investigated in 83.0% of the CT. The remaining studies investigated surgery or radiotherapy. A minority of papers were published in journals with impact factor (IF) higher than > 10 (16%) or in regions other than North America and Europe (20.4%). Overall, 83.1% of studies disclosed funding sources: 32.6% from industry alone, 33.9% from an academic or cooperative group, and 10.7% from a mixed funding model. COI data was reported by 85.9% of trials, of which 56.2% reported no COI and 43.8% reported a related COI. Significant predictors for sponsorship (industry and/or academia) on univariate analysis were study design, type of intervention, journal impact factor,
Journal of Neuro-Oncology – Springer Journals
Published: Jun 4, 2018
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.